Payment overview · 2025
General Payments
$279.37
16 reported records · 8 companies
Healthcare provider profile · identity verified
Chadwick E Gambrell, DO
Allopathic & Osteopathic Physicians|Family Medicine · PINEVILLE, KY · NPI 1578903118
Verified facts
What the public records show
CMS Open Payments records show Chadwick E Gambrell, DO received $279.37 in general payments during 2025 across 16 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $65.97 | 23.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.90 | 16.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.00 | 12.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.85 | 12.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.34 | 11.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.95 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.31 | 7.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.05 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.37 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $65.97 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.00 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.85 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 357 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 261 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 31 |
| Omeprazole | Omeprazole | 196 | 56 |
| Furosemide | Furosemide | 195 | 48 |
| Montelukast Sodium | Montelukast Sodium | 188 | 39 |
| Metformin Hcl | Metformin Hcl | 181 | 37 |
| Prednisone | Prednisone | 176 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 169 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 46 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 163 | 30 |
| Simvastatin | Simvastatin | 161 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 43 |
| Potassium Chloride | Potassium Chloride | 157 | 37 |
| Gabapentin | Gabapentin | 152 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 141 | 30 |
| Carvedilol | Carvedilol | 137 | 38 |
| Trazodone Hcl | Trazodone Hcl | 128 | 24 |
| Methylprednisolone | Methylprednisolone | 126 | 88 |
| Buspirone Hcl | Buspirone Hcl | 121 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 114 | 24 |
| Losartan Potassium | Losartan Potassium | 113 | 21 |
| Valsartan | Valsartan | 113 | 32 |
| Atenolol | Atenolol | 112 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 23 |
| Eliquis | Apixaban | 97 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 26 |
| Meloxicam | Meloxicam | 91 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 23 |
| Baclofen | Baclofen | 90 | 25 |
| Ibuprofen | Ibuprofen | 89 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 41 |
| Ondansetron Odt | Ondansetron | 88 | 30 |
| Clonazepam | Clonazepam | 87 | 11 |
| Jardiance | Empagliflozin | 87 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 59 |
| Alprazolam | Alprazolam | 79 | suppressed |
| Celecoxib | Celecoxib | 79 | 22 |
| Famotidine | Famotidine | 74 | 19 |
| Clonidine Hcl | Clonidine Hcl | 73 | 16 |
| Diazepam | Diazepam | 73 | suppressed |
| Glipizide | Glipizide | 70 | 17 |
| Mounjaro | Tirzepatide | 68 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 12 |
| Topiramate | Topiramate | 62 | 11 |
| Tramadol Hcl | Tramadol Hcl | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 11 |
| Meclizine Hcl | Meclizine Hcl | 61 | 16 |
| Levofloxacin | Levofloxacin | 60 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | suppressed |
| Allopurinol | Allopurinol | 55 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 54 | suppressed |
| Azithromycin | Azithromycin | 54 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 12 |
| Pregabalin | Pregabalin | 54 | 11 |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Cefdinir | Cefdinir | 49 | 44 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Methocarbamol | Methocarbamol | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Ozempic | Semaglutide | 40 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Linzess | Linaclotide | 38 | 13 |
| Promethazine Hcl | Promethazine Hcl | 37 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Mupirocin | Mupirocin | 28 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 16 |
| Fluconazole | Fluconazole | 25 | 18 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Cephalexin | Cephalexin | 15 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Intuniv | Guanfacine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.37 · 16 records | VERTEX PHARMACEUTICALS INCORPORATED | Auvelity, JOURNAVX, Kerendia, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error